| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Vera Therapeutics, Inc.
13D/A
VERA · 92337R101
|
4.0% |
3/5/2026
Event 12/10/2025
|
||||
| Sofinnova Venture Partners X, L.P. ("SVP X") | 3.9% | |||||
| Sofinnova Management X, L.P. ("SM X LP") | 3.9% | |||||
| Sofinnova Management X-A, L.L.C. ("SM X LLC") | 3.9% | |||||
| Dr. James I. Healy ("Healy") | 3.9% | |||||
| Dr. Maha Katabi ("Katabi") | 4.0% | |||||
|
Jade Biosciences, Inc.
13D/A
JBIO · 008064206
|
0.3% |
3/5/2026
Event 4/28/2025
|
||||
| Sofinnova Venture Partners X, L.P. ("SVP X") | 0.3% | |||||
| Sofinnova Management X, L.P. ("SM X LP") | 0.3% | |||||
| Sofinnova Management X-A, L.L.C. ("SM X LLC") | 0.3% | |||||
| Dr. James I. Healy ("Healy") | 0.3% | |||||
| Dr. Maha Katabi ("Katabi") | 0.3% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.